Using patient-specific stem cells, tissue engineering, and omics technologies to develop precision medicine for cardiovascular disease.

The Bann Laboratory focuses on discovering novel mechanistic targets to treat heart failure. We aim to identify regulators of cardiac cell fate reprogramming and regeneration as a molecular strategy to repair and heal the heart following injury.

The Singal & Rich research group focuses on generating critical insights to improve the entire spectrum of liver cancer care. Our studies involve assessing and promoting novel practices, imaging, and blood-based biomarkers to improve risk stratification, screening, early detection and outcomes for patients with hepatocellular carcinoma and other primary liver cancers.  

Drapkin Lab investigates the molecular drivers of oncogenesis, metastasis, and chemoresistance in small cell lung cancer (SCLC) to discover new therapeutic targets. 

The Mosley Lab develops and applies innovative genomic and informatics approaches to identify opportunities to use genetic background to inform clinical and public health decision-making, to identify risk factors and biomarkers of disease, and to identify and reduce heath inequities in vulnerable populations. 

We investigate the neuroepigenetic mechanisms regulating synaptic plasticity in the hypothalamus, their role in maintaining body weight set-point, and how their dysregulation contributes to diet-induced obesity, weight-regain, and aging-related impairments in appetite.

Our current research is focused on biochemical and structural studies of how membrane molecules signal to the actin cytoskeleton through a large, five-protein complex named the WAVE Regulatory Complex (WRC). 

Muto lab leverages both cutting-edge wet-lab and multi-omics approaches to understand gene regulatory mechanism driving kidney diseases. Current projects are focused on acute kidney injury and polycystic kidney disease.

Research lab led by Connie Hsia, M.D., in the Biomedical Engineering Graduate Program of UT Southwestern Medical School.

Leveraging cutting-edge genetic and chemical screens to uncover novel and enhanced therapeutics for cancer treatment.